Effects of 12-O-tetradecanoyl phorbol 13-acetate on platelet aggregation

T. M. Chiang, L. M. Cagen, Andrew Kang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A tumor promotor, 12-O-tetradecanoyl-phorbol-13-acetate (TPA) from croton oil can cause human platelets to aggregate and to release [14C]-serotonin from platelets. This promotor causes an increase in the cGMP content of platelets and a slight decrease in the platelet cAMP content. It also increases endogenous phosphorylation of four major platelet protein bands of apparent molecular weight of 47,000, 72,000, 90,000 and 130,000 daltons, respectively. TPA does not induce formation of thromboxane A2 by platelets and the promotor induced platelet aggregation is not inhibited by aspirin. These observations suggest that TPA-induced platelet aggregation may not be mediated by thromboxane A2 formation, but by alterations in the platelet membrane structure.

Original languageEnglish (US)
Pages (from-to)611-622
Number of pages12
JournalThrombosis Research
Volume21
Issue number6
DOIs
StatePublished - Mar 15 1981

Fingerprint

Tetradecanoylphorbol Acetate
Platelet Aggregation
Blood Platelets
Thromboxane A2
Acetates
Croton Oil
Aspirin
Serotonin
Molecular Weight
Phosphorylation
Membranes
Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Effects of 12-O-tetradecanoyl phorbol 13-acetate on platelet aggregation. / Chiang, T. M.; Cagen, L. M.; Kang, Andrew.

In: Thrombosis Research, Vol. 21, No. 6, 15.03.1981, p. 611-622.

Research output: Contribution to journalArticle

Chiang, T. M. ; Cagen, L. M. ; Kang, Andrew. / Effects of 12-O-tetradecanoyl phorbol 13-acetate on platelet aggregation. In: Thrombosis Research. 1981 ; Vol. 21, No. 6. pp. 611-622.
@article{6235ce8decf14d3894ae6d486315e3d2,
title = "Effects of 12-O-tetradecanoyl phorbol 13-acetate on platelet aggregation",
abstract = "A tumor promotor, 12-O-tetradecanoyl-phorbol-13-acetate (TPA) from croton oil can cause human platelets to aggregate and to release [14C]-serotonin from platelets. This promotor causes an increase in the cGMP content of platelets and a slight decrease in the platelet cAMP content. It also increases endogenous phosphorylation of four major platelet protein bands of apparent molecular weight of 47,000, 72,000, 90,000 and 130,000 daltons, respectively. TPA does not induce formation of thromboxane A2 by platelets and the promotor induced platelet aggregation is not inhibited by aspirin. These observations suggest that TPA-induced platelet aggregation may not be mediated by thromboxane A2 formation, but by alterations in the platelet membrane structure.",
author = "Chiang, {T. M.} and Cagen, {L. M.} and Andrew Kang",
year = "1981",
month = "3",
day = "15",
doi = "10.1016/0049-3848(81)90262-0",
language = "English (US)",
volume = "21",
pages = "611--622",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Effects of 12-O-tetradecanoyl phorbol 13-acetate on platelet aggregation

AU - Chiang, T. M.

AU - Cagen, L. M.

AU - Kang, Andrew

PY - 1981/3/15

Y1 - 1981/3/15

N2 - A tumor promotor, 12-O-tetradecanoyl-phorbol-13-acetate (TPA) from croton oil can cause human platelets to aggregate and to release [14C]-serotonin from platelets. This promotor causes an increase in the cGMP content of platelets and a slight decrease in the platelet cAMP content. It also increases endogenous phosphorylation of four major platelet protein bands of apparent molecular weight of 47,000, 72,000, 90,000 and 130,000 daltons, respectively. TPA does not induce formation of thromboxane A2 by platelets and the promotor induced platelet aggregation is not inhibited by aspirin. These observations suggest that TPA-induced platelet aggregation may not be mediated by thromboxane A2 formation, but by alterations in the platelet membrane structure.

AB - A tumor promotor, 12-O-tetradecanoyl-phorbol-13-acetate (TPA) from croton oil can cause human platelets to aggregate and to release [14C]-serotonin from platelets. This promotor causes an increase in the cGMP content of platelets and a slight decrease in the platelet cAMP content. It also increases endogenous phosphorylation of four major platelet protein bands of apparent molecular weight of 47,000, 72,000, 90,000 and 130,000 daltons, respectively. TPA does not induce formation of thromboxane A2 by platelets and the promotor induced platelet aggregation is not inhibited by aspirin. These observations suggest that TPA-induced platelet aggregation may not be mediated by thromboxane A2 formation, but by alterations in the platelet membrane structure.

UR - http://www.scopus.com/inward/record.url?scp=0019455791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019455791&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(81)90262-0

DO - 10.1016/0049-3848(81)90262-0

M3 - Article

C2 - 6267728

AN - SCOPUS:0019455791

VL - 21

SP - 611

EP - 622

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -